Applied StemCell, Inc.
521 Cottonwood Dr, Suite 111
8 articles with Applied StemCell, Inc.
Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy
Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility.
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell's Gene Editing Platform and Oncology Product Portfolio
Transaction adds comprehensive gene editing capabilities and engine to drive expansion of Abcam's 'off-the-shelf' edited cell line portfolio
Applied StemCell Advances TARGATT™ Gene-Editing Technology for Mammalian Cell Line Bioproduction Applications
Applied StemCell is excited to announce the recent publication of A System for Site-specific Integration of Transgenes in Mammalian Cells in PLOS ONE.
ASC Therapeutics Licenses Critical Technologies for Hemophilia A Gene Therapy from Expression Therapeutics
ASC Therapeutics, A Division of Applied StemCell, Inc., announced that it has obtained an exclusive therapeutics license from Expression Therapeutics, LLC for coagulation factor VIII expression technologies including a highly compact, yet potent, liver-directed promoter and matching liver-codon optimized factor VIII transgene for adeno-associated viral vector gene therapy of hemophilia A.
Applied StemCell, Inc. announced that its therapeutic division has cured Hemophilia A in mice and will be presenting their in vivo and in vitro findings at the 22nd Annual Meeting of The American Society of Gene and Cell Therapy held April 29 – May 2 in Washington D.C.
SeraCare to offer AccuRef cancer reference materials alongside their Seraseq® portfolio of NGS cancer products
Applied StemCell, Inc. (ASC), a leading gene-editing company, announced that it has joined the National Institute of Standards and Technology (NIST) Genome Editing Consortium